Trial Profile
A prospective study to evaluate the reduction of PD-L1 expression due to sample age in patients with non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 14 Jun 2021 Status changed from recruiting to completed.
- 05 Jul 2018 Planned number of patients changed from 40 to 60.
- 18 Dec 2017 New trial record